Summary
BeOne Medicines Ltd. (ONC), through its collaboration with EUSA Pharma (UK) Limited, announced a significant development on November 9, 2020, with the acceptance of their Biologics License Application (BLA) for QARZIBA®▼ (dinutuximab beta) by the China National Medical Products Administration (NMPA). The application has also been granted priority review, indicating a potentially accelerated pathway to market in China. QARZIBA®▼ is a targeted immunotherapy currently approved by the European Medicines Agency (EMA) for high-risk neuroblastoma in specific patient populations, including those with relapsed or refractory disease. This regulatory milestone in China represents a key step for the drug's potential global expansion and market access.
Key Highlights
- 1BeiGene and EUSA Pharma announced NMPA acceptance of the BLA for QARZIBA®▼ (dinutuximab beta) in China.
- 2The BLA for QARZIBA®▼ has been granted priority review by the NMPA.
- 3QARZIBA®▼ is a targeted immunotherapy for high-risk neuroblastoma.
- 4The drug is indicated for patients aged 12 months and above with specific treatment histories or relapsed/refractory disease.
- 5High-risk neuroblastoma is a common and aggressive childhood solid tumor.
- 6QARZIBA®▼ is listed by the NMPA as a New Drug in Urgent Clinical Need Marketed Overseas.
- 7This filing was made on November 9, 2020.
Frequently Asked Questions
QARZIBA®▼ (dinutuximab beta) is a targeted immunotherapy. Its primary indication is for the treatment of high-risk neuroblastoma in patients aged 12 months and above. This includes patients who have received specific prior treatments like induction chemotherapy and stem cell transplantation, as well as those with a history of relapsed or refractory neuroblastoma.
The acceptance of the Biologics License Application (BLA) by the China National Medical Products Administration (NMPA) signifies that the regulatory body has deemed the application complete enough for substantive review. The 'priority review' designation suggests that the NMPA will expedite the review process, potentially leading to a faster approval decision compared to standard reviews. This is a significant step towards making QARZIBA®▼ available to patients in China.
This listing indicates that the NMPA recognizes QARZIBA®▼ as a drug with significant unmet medical needs in China and that it has already been approved and marketed in other major overseas markets (like Europe, as per the EMA approval mentioned). This recognition can further streamline the regulatory process and highlights the drug's potential benefit for Chinese patients.